initial public offerings (IPOs) trading on American exchanges

Saturday, June 13, 2015

KemPharm (KMPH) began trading on the NASDAQ on 16 April 2015

KemPharm, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of new molecular entity (NME) prodrugs. The Company, through its Ligand Activated Therapy (LAT) platform technology, creates NME prodrug product candidates. The Company's NME prodrug product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder (ADHD), and KP303 for the treatment of central nervous system (CNS) disorders. The Company's product's KP201/APAP is in clinical trial stage, and KP511/ER, KP415, KP606/ER and KP303 are in preclinical trail stage.


2656 Crosspark Road, Suite 100
United States

No comments:

Post a Comment